Composition for Preserving Platelets and Method of Using the Same

• US 20110223579A1
• Filed: 05/02/2011
• Published: 09/15/2011
• Est. Priority Date: 01/12/2005
• Status: Active Grant

• Current Assignee: Biovec Transfusion LLC
• Original Assignee: Biovec Transfusion LLC
• Inventors: SEHGAL, Lakshman R.
• Granted Patent: US 8,232,044 B2
• Time in Patent Office: Days
• US Class Current: 435/2
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients

Abstract

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Claims

1-19. -19. (canceled)

20. A method of extending the shelf-life of platelets, comprising the steps of:

(a) admixing a preservative composition with inactivated, functional platelets to provide a preserved platelet composition; and

(b) store the preserved platelet composition in an oxygen-permeable container or an oxygen-impermeable container,

wherein the preservative composition comprises a single antiplatelet agent, an anticoagulant that reversibly inhibits factor IIa, and a hemoglobin-based oxygen carrier at a concentration range of 1-18 gm/dl, wherein said antiplatelet agent is eptifibatide.

21. The method of claim 20, wherein said inactivated, functional platelets are substantially free of red blood cells and other blood nutrients.

26. The method of claim 20, wherein said preservative composition comprises said antiplatelet agent at a concentration of about 0.001 mg to about 5 mg per 50 ml.

27. The method of claim 20, wherein said anticoagulant is a short-to-ultrashort acting IIa inhibitor.

28. The method of claim 27, wherein said short-to-ultrashort acting IIa inhibitor is selected from the group consisting of hirudin, hirulog, melgatran, and combinations thereof.

29. The method of claim 20, wherein said preservative composition further comprises an anticoagulant that inhibits factor Xa.

30. The method of claim 29, wherein said anticoagulant that inhibits factor Xa is a short-to-ultrashort acting Xa inhibitor.

31. The method of claim 30, wherein said short-to-ultrashort acting Xa inhibitor is selected from the group consisting of DX-9065a, RPR-120844, BX-807834 and SEL series Xa inhibitors.

32. The method of claim 20, wherein said antiplatelet agent is conjugated to a nitric oxide donor.

33. The method of claim 20, wherein said hemoglobin-based oxygen carrier is substantially free of red cell membrane contaminants.

34. The method of claim 20, wherein said preservative composition further comprises an anti-microbial agent selected from the group consisting of:

penicillin, monobactam, cephalosporins, carbapenems, vancomycin, isoniazid, ethambutol, aminoglycosides, tetracycline, chloramphenicol, macrolides, rifamycin, quinolone, fluoroquinolone, sulfonamides, polyene antibiotics, imidazole, triazole, griseofulvin and combinations thereof.

22-25. -25. (canceled)

35. A method of extending the shelf-life of platelets, comprising the steps of:

(a) admixing a preservative composition with inactivated, functional platelets to provide a preserved platelet composition; and

(b) store the preserved platelet composition in a container,

wherein the preservative composition comprises a short-to-ultrashort acting antiplatelet agent, a short-to-ultrashort acting anticoagulant; and

an oxygen carrier.

36. The method of claim 35, wherein said short-to-ultrashort acting antiplatelet agent is a GPIIb/IIIa inhibitor.

37. The method of claim 36, wherein said GPIIb/IIIa inhibitor is selected from the group consisting of XJ757, XR299, eptifibatide, orbofiban, xemilofiban, Lamifiban, tirofiban (Aggrastat), and mixtures thereof.

38. The method of claim 35, wherein said short-to-ultrashort acting anticoagulant is a compound that reversibly inhibits factor Xa, or factor IIa, or both.

39. The method of claim 35, wherein said short-to-ultrashort acting anticoagulant is selected from the group consisting of DX-9065a, BX-80783, RPR-120844, and SEL series Xa inhibitors.

40. The method of claim 35, wherein said short-to-ultrashort acting anticoagulant is selected from the group consisting of hirudin, hirulog, melgatran, and combinations thereof.

41. The method of claim 35, wherein said short-to-ultrashort acting anticoagulant is a combination of at least one short-to-ultrashort acting IIa inhibitor, and at least one short-to-ultrashort acting Xa inhibitor.

42. The method of claim 35, wherein said oxygen carrier is a pharmaceutically acceptable oxygen carrier and is selected from the group consisting of hemoglobin, ferroprotoporphyrin, perfluorochemicals, and mixtures thereof.

43. The composition of claim 35, wherein said oxygen carrier is a hemoglobin-based oxygen carrier.